Last updated: April 22, 2025
Sponsor: Mayo Clinic
Overall Status: Active - Recruiting
Phase
N/A
Condition
Melanoma
Skin Cancer
Treatment
Non-Interventional Study
Clinical Study ID
NCT06675643
23-011475
NCI-2024-09081
23-011475
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Any skin cancer/melanoma patient starting dual [ipilimumab/nivolumab (IPI/NIVO)]immune checkpoint inhibitor (ICI) therapy
Exclusion
Exclusion Criteria:
- Does not meet inclusion criteria
Study Design
Total Participants: 30
Treatment Group(s): 1
Primary Treatment: Non-Interventional Study
Phase:
Study Start date:
October 14, 2024
Estimated Completion Date:
March 15, 2026
Study Description
Connect with a study center
Mayo Clinic in Rochester
Rochester, Minnesota 55905
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.